Ellagic acid induced p53/p21 expression, G1 arrest and apoptosis in human bladder cancer T24 cells

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 971-979

  Li, Te Mao ^a   Chen, Guang Wei ^a   Su, Chin Cheng ^b   Lin, Jaung Gung ^a   Yeh, Chin Chung ^b   Cheng, Kwork Chu ^c   Chung, Jing Gung ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c JEN AI HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Caspase 3; Cell cycle arrest; Ellagic acid; P21; P53

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; CYCLIN DEPENDENT KINASE 2; ELLAGIC ACID; PHENOL DERIVATIVE; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; BLADDER CANCER; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOSIS INHIBITION; MOLECULAR BIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; AMINO ACID CHLOROMETHYL KETONES; APOPTOSIS; CASPASE 3; CASPASES; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; ELLAGIC ACID; ENZYME ACTIVATION; FEMALE; G1 PHASE; GENE EXPRESSION; HUMANS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 17444408529     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME and Huang Y: Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7: 563-568, 1993.
2. Kaufman SH: Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 49: 5870-5878, 1989.
3. Walker PR, Smith C, Youdale T, Leblanc J, Whitfield JF and Sikorska M: Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res 51: 1078-1085, 1991.
4. Ling YH, Priebe W and Perze SR: Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells. Cancer Res 53: 1845-1852, 1993.
5. Stevnsner T and Bohr VA: Studies on the role of topoisomerase in general, gene and strand-specific DNA repair. Carcinogenesis 14: 1841-1850, 1993.
6. Bate-Smith EC: Detection and determination of ellagitannins. Phytochemistry 11: 1153-1156, 1972.
7. Perchellet JP, Gali EM, Perchelle DS and Klish AD: Armbrust, antitumor promoting activities of tannin acid, ellagic acid, and several gallic acid derivatives in mouse skin, Basic Life Sci 59: 783-801, 1992.
8. Stoner GD and Morse AM: Isothiocyanates and plant polyphenols as inhibitors of lung and esophageal cancer. Cancer Lett 114: 113-119, 1997.
9. Dow LR, Chou TT, Bechle MB, Goddard C and Larson RE: Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine protein kinase inhibitors. J Med Chem 37: 224-231, 1994.
10. Barch DH, Rundhaugen LM, Stoner GD, Pillay NS and Rosche WA: Structure-function relationships of the dietary anticarcinogen ellagic acid. Carcinogenesis 17: 265-269, 1996.
11. Das M, Bickers DR and Mukhtar H: Effect of ellagic acid on hepatic and pulmonary xenobiotic metabolism in mice: studies on the mechanism of its anticarcinogenic action. Carcinogenesis 6: 1409-1413, 1985.
12. Ahn D, Putt D, Kresty L, Stoner GD, Fromm D and Hollenberg PF: The effects of dietary ellagic acid on rat hepatic and esophageal mucosal cytochromes p450 and phase II enzymes. Carcinogenesis 17: 821-828, 1996.
13. Chung JG: Inhibitory actions of ellagic acid on growth and arylamine N-acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients. Microbios 93: 115-127, 1998.
14. Lin SS, Hung CF, Tyan YS, Yang CC, Hsia TC, Yang MD and Chung JD: Ellagic acid inhibits arylamine N-acetyltransferase activity and DNA adduct formation in human bladder tumor cell lines (T24 and TSGH 8301). Urol Res 29: 371-376, 2001.
15. Teel RW: Ellagic acid binding to DNA as a possible mechanism for its antimutagenic and anticarcinogenic action. Cancer Lett 30: 329-336, 1986.
16. Thresiamma KC and Kuttan R: Inhibition of liver fibrosis by ellagic acid. Indian J Physiol Pharmacol 40: 363-366, 1996.
17. Narayanan BA, Geoffroy O, Willingham MC, Re GG and Nixon DW: P53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett 136: 215-221, 1999.
18. Narayanan BA and Re GG: IGF-II down-regulation associated cell cycle arrest in colon cancer cells exposed to phenolic antioxidant ellagic acid. Anticancer Res 21: 359-364, 2001.
19. Li YC, Tyan YS, Kuo HM, Chang WC, Hsia TC and Chung JG: Baicalein induced in vitro apoptosis undergo caspases activity in human promyelocytic leukemia HL-60 cells. Food Chem Toxicol 42: 37-43, 2004.
20. Ormerod MG: In: Flow Cytometry: A Practical Approach. Oxford University Press, New York, pp. 69-81, 1990.
21. Chung JG, Yeh KT, Wu SL, Chen GW, Hsu NY and Ho HC: Novel transmembrane GTPase of non-small cell lung cancer identified by mRNA differential display. Cancer Res 67: 8873-8879, 2001.
22. Drexler HG, Dirks W, MacLeod RAF, Quentmeier H, Steube K and Uphoff CC (eds): DSMZ Catalogue of Human and Animal Cell Lines, Seventh edition, Braunschweig, Germany, 1999.
23. Chang BD, Swift ME, Shen M, Fang J, Broude EV and Roninson IB: Molecular determinants of terminal growth arrest induced in tumor cells by chemotherapeutic agent. Proc Natl Acad Sci USA 99: 389-394, 2002.
24. Han Z, Wei W, Dunaway S, Darnowski JW, Calabresi P, Sedivy J, Hendrickson EA, Balan KV, Pantazis P and Wyche JH: Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J Biol Chem 277: 17154-17160, 2002.
25. Zhou BP, Liao Y, Xia W, Sophn B, Lee MH and Hung MC: Cytoplasmic localization of p21CIP1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3: 245-252, 2001.
26. Wyllie AH, Kerr RG and Currie AR: Cell death: the significance of apoptosis. Int Rev Cytol 68: 251-306, 1980.
27. Kerr JFR, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
28. Li H, Alonso-Vanegas M, Colicos MA, Jung SS, Lochmuller H, Sadikot AF, Snipes GJ, Seth P, Karpati G and Nalbantoglu J: Intracerebral adenovirus-mdiated p53 tumor suppressor gene therapy for experimental human glioma. Clin Cancer Res 5: 637-642, 1999.
29. Hsiao M, Tse V, Carmel J, Tsai Y, Felgner PL, Haas M and Silverberg GD: Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo in tumor suppression and long-term survival. Biochem Biophys Res Commun 233: 359-364, 1997.
30. Yu JL, Coomber BL and Kerbel RS: A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation 70: 599-609, 2002.
31. Ibrado AM, Huang Y, Fang G, Liu L and Bhalla K: Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 56: 4743-4748, 1996.
32. Ohta T, Kinoshita T, Naito M, Nozaki T, Masutani M, Tsuro T and Miyajima A: Requirement of the caspase-3/CP32 protease cascade for apoptotic death following cytokine deprivation in hematopoietic cells. J Biol Chem 272: 23111-23116, 1997.
33. Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Develop 13: 1899-911, 1999.
34. Vander Heiden MG and Thompson CB: Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis. Nature Cell Biol 1: E209-16, 1999.
35. Zhang H, Huang Q, Ke N, Matsuyama S, Hammock B, Godzik A and Reed JC: Drosophila pro-apoptotic Bcl-2/Bax homologue reveals evolutionary conservation of cell death mechanism. J Biol Chem 275: 27303-6, 2000.
36. Yano H, Mizoguchi A, Fukuda K, Haramaki M, Ogasawara S, Momosaki S and Kojiro M: The herbal medicine sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase. Cancer Res 54, 448-454, 1994.